Skip to main content
. Author manuscript; available in PMC: 2018 Oct 7.
Published in final edited form as: Lancet. 2017 Aug 3;390(10103):1664–1675. doi: 10.1016/S0140-6736(17)31585-4

Table 1.

Patient characteristics at baseline

Exenatide (n=31) Placebo (n=29)
Age, years 61·6 (8·2) 57·8 (8·0)
Sex
 Female 9 (29%) 7 (24%)
 Male 22 (71%) 22 (76%)
Age at diagnosis, years 55·9 (7·9) 52·2 (7·7)
Duration of diagnosis at baseline, years 6·4 (3·3) 6·4 (3·3)
Hoehn and Yahr stage
 1·0–2·0 29 (94%) 29 (100%)
 2·5 2 (6%) 0 (0%)
MDS-UPDRS part 3 off medication 32·8 (9·7) 27·1 (10·3)
Levodopa equivalent dose, mg 773·9 (260·9) 825·7 (215·0)

Data are mean (SD) or n (%). This table excludes two patients who were recruited but did not complete any follow-up visits. MDS-UPDRS=Movement Disorders Society Unified Parkinson’s Disease Rating Scale.